Yıl: 2023 Cilt: 4 Sayı: 1 Sayfa Aralığı: 19 - 24 Metin Dili: İngilizce DOI: 10.14744/hf.2022.2022.0010 İndeks Tarihi: 04-06-2023

Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis

Öz:
Background and Aim: Hepatic encephalopathy (HE) is a frequent compli- cation of liver diseases. Systemic inflammation is key for HE pathogenesis. The main goal of the study was to investigate the role of psychometric tests, critical flicker frequency (CFF), and comparative evaluation of inflammato- ry indicators for the diagnosis of covert HE (CHE). Materials and Methods: The study was a prospective, nonrandomized, case–control study with a total of 76 cirrhotic patients and 30 healthy vol- unteers. The West Haven criteria were used to determine the occurrence of CHE in cirrhotic patients. Psychometric tests were applied to healthy and cirrhotic groups. CFF, venous ammonia, serum endotoxin, IL-6, IL-18, tu- mor necrosis factor alpha (TNF-α) levels, and hemogram parameters were evaluated for cirrhotic patients. Results: CFF values and psychometric tests were found to accurately dis- criminate CHE positives from CHE negatives (p<0.05). When the control group was excluded, the digit symbol test and the number connection A test failed, unlike CFF and other psychometric tests. Using CFF, a 45 Hz cutoff value had 74% specificity and 75% sensitivity. Basal albumin levels (p=0.063), lymphocyte-to-monocyte ratio (LMR) (p=0.086), and neutro- phil-to-lymphocyte ratio (p 0.052) were significant, albeit slightly, among CHE groups. Basal albumin levels had 50% sensitivity and 71% specificity when 2.8 g/dL was used as a cutoff value to determine CHE. Conclusion: Both psychometric tests and CFF can be useful in diagnosing CHE. Using cytokine and endotoxin levels seems to be inadequate to diag- nose CHE. Using LMR and albumin levels instead of psychometric tests for diagnosing CHE can be promising.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Córdoba J. New assessment of hepatic encephalopathy. J Hepatol 2011;54(5):1030-1040. [CrossRef]
  • 2. Amodio P. Hepatic encephalopathy: Diagnosis and management. Liver Int 2018;38(6):966-975. [CrossRef]
  • 3. Weissenborn K, Ennen JC, Schomerus H, Rückert N, Hecker H. Neu- ropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34(5):768-773. [CrossRef]
  • 4. Ridola L, Cardinale V, Riggio O. The burden of minimal hepatic enceph- alopathy: from diagnosis to therapeutic strategies. Ann Gastroenterol 2018;31(2):151-164. [CrossRef]
  • 5. Li SW, Wang K, Yu YQ, Wang HB, Li YH, Xu JM. Psychometric hepatic encephalopathy score for diagnosis of minimal hepatic encephalopathy in China. World J Gastroenterol 2013;19(46):8745-8751. [CrossRef]
  • 6. American Association for the Study of Liver Diseases; European Associ- ation for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014;61(3):642-659. [CrossRef]
  • 7. Nabi E, Bajaj JS. Useful tests for hepatic encephalopathy in clinical prac- tice. Curr Gastroenterol Rep 2014;16(1):362. [CrossRef]
  • 8. Sharma P, Sharma BC, Sarin SK. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis. Hepatobiliary Pancreat Dis Int 2010;9(1):27-32.
  • 9. Luo M, Guo JY, Cao WK. Inflammation: A novel target of current thera- pies for hepatic encephalopathy in liver cirrhosis. World J Gastroenterol 2015;21(41):11815-11824. [CrossRef]
  • 10. Montoliu C, Cauli O, Urios A, ElMlili N, Serra MA, Giner-Duran R, et al. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalop- athy in patients with liver cirrhosis. Am J Gastroenterol 2011;106(9):1629-1637. [CrossRef]
  • 11. Rice J, Dodge JL, Bambha KM, Bajaj JS, Reddy KR, Gralla J, et al. neutro- phil-to-lymphocyte ratio associates independently with mortality in hospital- ized patients with cirrhosis. Clin Gastroenterol Hepatol 2018;16(11):1786-1791.e1. [CrossRef]
  • 12. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepa- tology 2009;50(6):2014-2021. [CrossRef]
  • 13. Shaw J, Bajaj JS. Covert hepatic encephalopathy: Can my patient drive? J Clin Gastroenterol 2017;51(2):118-126. [CrossRef]
  • 14. Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: Diagnosis and management. Clin Gastroenterol Hepatol 2015;13(12):2048-2061. [CrossRef]
  • 15. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and nat- ural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroen- terol Hepatol. 2001;16(5):531-535. [CrossRef]
  • 16. Bajaj JS. Review article: the modern management of hepatic encephalopa- thy. Aliment Pharmacol Ther 2010;31(5):537-547. [CrossRef]
  • 17. Neff G, Zachry W III. Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin. Phar- macoeconomics 2018;36(7):809-822. [CrossRef]
  • 18. Stepanova M MA, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012;10(9):1034- 1041. [CrossRef]
  • 19. Tapper EB, Parikh ND, Waljee AK, Volk M, Carlozzi NE, Lok AS. Diagno- sis of minimal hepatic encephalopathy: a systematic review of point-of-care diagnostic tests. Am J Gastroenterol 2018;113(4):529-538. [CrossRef]
  • 20. vom Dahl S, Kircheis G, Häussinger D. Hepatic encephalopathy as a compli- cation of liver disease. World J Gastroenterol 2001;7(2):152-156. [CrossRef]
  • 21. Conn H. Subclinical hepatic encephalopathy. In Ed Conn HO, Bircher J (ed- itors). Hepatic Encephalopathy: Syndromes and Therapies. East Lansing, Michigan: Medi-Ed Press; 1994, 27-42.
  • 22. Duarte-Rojo A, Allampati S, Thacker LR, Flud CR, Patidar KR, White MB, et al. Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing. Metab Brain Dis 2019;34(1):289-295. [CrossRef]
  • 23. Torlot FJ, McPhail MJW, Taylor-Robinson SD. Meta-analysis: the diagnos- tic accuracy of critical flicker frequency in minimal hepatic encephalopathy. Aliment Pharmacol Ther 2013;37(5):527-536. [CrossRef]
  • 24. Ge PS, Runyon BA. Serum ammonia level for the evaluation of hepatic Encephalopathy. JAMA 2014;312(6):643-644. [CrossRef]
  • 25. Cooper AJ, Jeitner TM. Central role of glutamate metabolism in the mainte- nance of nitrogen homeostasis in normal and hyperammonemic brain. Bio- molecules 2016;6(2):16. [CrossRef]
  • 26. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, et al. Correlation between ammonia levels and the severity of hepatic encepha- lopathy. Am J Med 2003;114(3):188-193. [CrossRef]
  • 27. Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic enceph- alopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol 2015;5(Suppl 1):S7-S20. [CrossRef]
  • 28. Montoliu C, Piedrafita B, Serra MA, del Olmo JA, Urios A, Rodrigo JM, et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and with- out minimal hepatic encephalopathy. J Clin Gastroenterol 2009;43(3):272- 279. [CrossRef]
  • 29. Odeh M, Sabo E, Srugo I, Oliven A. Relationship between tumor necrosis factor-alpha and ammonia in patients with hepatic encephalopathy due to chronic liver failure. Ann Med 2005;37(8):603-612. [CrossRef]
  • 30. Jain L, Sharma BC, Sharma P, Srivastava S, Agrawal A, Sarin SK. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy. Dig Liver Dis 2012;44(12):1027-1031. [CrossRef]
  • 31. Felipo V, Urios A, Valero P, Sánchez M, Serra MA, Pareja I, et al. Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy. Liver Int 2013;33(10):1478-1489. [CrossRef]
  • 32. Bai Z, Guo X, Tacke F, Li Y, Li H, Qi X. Association of serum albu- min level with incidence and mortality of overt hepatic encephalop- athy in cirrhosis during hospitalization. Therap Adv Gastroenterol 2019;12:1756284819881302. [CrossRef]
  • 33. Kosuke K, Kiwamu O, Kazuyuki S, Ikuya S, Masaki F, Hitoshi Y. Lower levels of serum albumin are associated with impairment of cognitive func- tion in cirrhotic patients with early-stage hepatic encephalopathy: An ex- ploratory data analysis of phase II/III clinical trials of rifaximin in Japan. Research Square. Preprint. 2021. doi: 10.21203/rs.3.rs-17636/v1 [CrossRef]
  • 34. Zhang J, Feng G, Zhao Y, Zhang J, Feng L, Yang J. Association between lym- phocyte-to-monocyte ratio (LMR) and the mortality of HBV-related liver cir- rhosis: a retrospective cohort study. BMJ Open 2015;5(8):e008033. [CrossRef]
  • 35. Zhang H, Sun Q, Mao W, Fan J, Ye B. Neutrophil-to-lymphocyte ratio pre- dicts early mortality in patients with HBV-related decompensated cirrhosis. Gastroenterol Res Pract 2016;2016:4394650. [CrossRef]
APA Demirciler E, Danis N, Ergun P, KÖSE T, TURAN I, gunsar f, Akarca U, Ersoz G, karasu z (2023). Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. , 19 - 24. 10.14744/hf.2022.2022.0010
Chicago Demirciler Erkut,Danis Nilay,Ergun Pelin,KÖSE Timur,TURAN ILKER,gunsar fulya,Akarca Ulus Salih,Ersoz Galip,karasu zeki Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. (2023): 19 - 24. 10.14744/hf.2022.2022.0010
MLA Demirciler Erkut,Danis Nilay,Ergun Pelin,KÖSE Timur,TURAN ILKER,gunsar fulya,Akarca Ulus Salih,Ersoz Galip,karasu zeki Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. , 2023, ss.19 - 24. 10.14744/hf.2022.2022.0010
AMA Demirciler E,Danis N,Ergun P,KÖSE T,TURAN I,gunsar f,Akarca U,Ersoz G,karasu z Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. . 2023; 19 - 24. 10.14744/hf.2022.2022.0010
Vancouver Demirciler E,Danis N,Ergun P,KÖSE T,TURAN I,gunsar f,Akarca U,Ersoz G,karasu z Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. . 2023; 19 - 24. 10.14744/hf.2022.2022.0010
IEEE Demirciler E,Danis N,Ergun P,KÖSE T,TURAN I,gunsar f,Akarca U,Ersoz G,karasu z "Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis." , ss.19 - 24, 2023. 10.14744/hf.2022.2022.0010
ISNAD Demirciler, Erkut vd. "Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis". (2023), 19-24. https://doi.org/10.14744/hf.2022.2022.0010
APA Demirciler E, Danis N, Ergun P, KÖSE T, TURAN I, gunsar f, Akarca U, Ersoz G, karasu z (2023). Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. Hepatology forum, 4(1), 19 - 24. 10.14744/hf.2022.2022.0010
Chicago Demirciler Erkut,Danis Nilay,Ergun Pelin,KÖSE Timur,TURAN ILKER,gunsar fulya,Akarca Ulus Salih,Ersoz Galip,karasu zeki Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. Hepatology forum 4, no.1 (2023): 19 - 24. 10.14744/hf.2022.2022.0010
MLA Demirciler Erkut,Danis Nilay,Ergun Pelin,KÖSE Timur,TURAN ILKER,gunsar fulya,Akarca Ulus Salih,Ersoz Galip,karasu zeki Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. Hepatology forum, vol.4, no.1, 2023, ss.19 - 24. 10.14744/hf.2022.2022.0010
AMA Demirciler E,Danis N,Ergun P,KÖSE T,TURAN I,gunsar f,Akarca U,Ersoz G,karasu z Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. Hepatology forum. 2023; 4(1): 19 - 24. 10.14744/hf.2022.2022.0010
Vancouver Demirciler E,Danis N,Ergun P,KÖSE T,TURAN I,gunsar f,Akarca U,Ersoz G,karasu z Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis. Hepatology forum. 2023; 4(1): 19 - 24. 10.14744/hf.2022.2022.0010
IEEE Demirciler E,Danis N,Ergun P,KÖSE T,TURAN I,gunsar f,Akarca U,Ersoz G,karasu z "Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis." Hepatology forum, 4, ss.19 - 24, 2023. 10.14744/hf.2022.2022.0010
ISNAD Demirciler, Erkut vd. "Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis". Hepatology forum 4/1 (2023), 19-24. https://doi.org/10.14744/hf.2022.2022.0010